Giuseppe Altavilla

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer

Giorgio V. Scagliotti, Filippo de Marinis, Monica Rinaldi et al. · Journal of Clinical Oncology · 2002 · 891 citations

Medicine, Oncology, Pharmacology +13

Cisplatin Induces a Mitochondrial-ROS Response That Contributes to Cytotoxicity Depending on Mitochondrial Redox Status and Bioenergetic Functions

Rossella Marullo, Erica Werner, Natalya Degtyareva et al. · PLoS ONE · 2013 · 780 citations · Full text

Life Sciences, Cell Biology, Oncology +15

Natural killer cells infiltrating human nonsmall‐cell lung cancer are enriched in CD56^brightCD16⁻ cells and display an impaired capability to kill tumor cells

Paolo Carrega, Barbara Morandi, Roberta Costa et al. · Cancer · 2008 · 368 citations · Full text

Life Sciences, Immunology, Oncology +12

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

Lucio Crinò, Giorgio V. Scagliotti, M. Marangolo et al. · Journal of Clinical Oncology · 1997 · 308 citations

Medicine, Oncology, Pharmacology +17